{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:34:54Z","timestamp":1765546494145,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.vaccine.2019.09.033","type":"journal-article","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T08:03:05Z","timestamp":1569312185000},"page":"6682-6687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Serologic response to meningococcal vaccination in patients with cold agglutinin disease (CAD) in the novel era of complement inhibition"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7530-8892","authenticated-orcid":false,"given":"Ferras","family":"Alashkar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Vance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00f6rte","family":"Herich-Terh\u00fcrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin T.","family":"Turki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Bommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"H\u00fcttmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"D\u00fchrsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-7699","authenticated-orcid":false,"given":"Alexander","family":"R\u00f6th","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.09.033_b0005","first-page":"460","article-title":"Primary chronic cold agglutinin disease: a population based clinical study of 86 patients","volume":"91","author":"Berentsen","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.vaccine.2019.09.033_b0010","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/bloodadvances.2017004390","article-title":"Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization","volume":"1","author":"Mullins","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.vaccine.2019.09.033_b0015","first-page":"226","article-title":"Cold agglutinin disease Hematology. American Society of Hematology","author":"Berentsen","year":"2016","journal-title":"Education Program"},{"key":"10.1016\/j.vaccine.2019.09.033_b0020","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/bjh.15109","article-title":"How I manage patients with cold agglutinin disease","volume":"181","author":"Berentsen","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.vaccine.2019.09.033_b0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Population Health Metrics"},{"key":"10.1016\/j.vaccine.2019.09.033_b0030","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.09.033_b0035","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00277-017-2924-y","article-title":"Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab","volume":"96","author":"Alashkar","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.vaccine.2019.09.033_b0040","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/bloodadvances.2018024190","article-title":"Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial","volume":"2","author":"R\u00f6th","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.vaccine.2019.09.033_b0045","unstructured":"CHMP. SOLIRIS, INN: eculizumab. At <https:\/\/www.ema.europa.eu\/documents\/scientific-discussion\/soliris-epar- scientific-discussion_en.pdf>."},{"key":"10.1016\/j.vaccine.2019.09.033_b0050","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1586\/14760584.3.1.77","article-title":"Serologic correlates of protection for evaluating the response to meningococcal vaccines","volume":"3","author":"Balmer","year":"2004","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.09.033_b0055","unstructured":"Public Health Agency of Canada. An advisory committee statement (ACS) \u2013 National Advisory Committee on Immunization (NACI)\u202f: Update on quadrivalent meningococcal vaccines available in Canada. At <https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/update-quadrivalent-meningococcal-vaccines-available-canada.html>."},{"key":"10.1016\/j.vaccine.2019.09.033_b0060","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1745-6673-8-4","article-title":"Persistence of antibodies in laboratory staff immunized with quadrivalent meningococcal polysaccharide vaccine","volume":"8","author":"Elias","year":"2013","journal-title":"J Occup Med Toxicol (London, England)"},{"key":"10.1016\/j.vaccine.2019.09.033_b0065","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4161\/viru.26515","article-title":"Meningococcal disease and the complement system","volume":"5","author":"Lewis","year":"2014","journal-title":"Virulence"},{"key":"10.1016\/j.vaccine.2019.09.033_b0070","unstructured":"Search of: Cold Agglutinin Disease \u2013 List Results \u2013 ClinicalTrials.gov. At <https:\/\/clinicaltrials.gov\/ct2\/results?cond=Cold+Agglutinin+Disease&term=&cn try=&state=&city=&dist=>."},{"key":"10.1016\/j.vaccine.2019.09.033_b0075","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1128\/IAI.01044-09","article-title":"Critical roles of complement and antibodies in host defense mechanisms against Neisseria meningitidis as revealed by human complement genetic deficiencies","volume":"78","author":"Hellerud","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.09.033_b0080","unstructured":"Parliament and of the Council for \u201cTrumenba-meningococcal group B vaccine (recombinant, adsorbed)\u201d, a medicinal product for human use (Text with EEA relevance) (ONLY THE ENGLISH TEXT IS AUTHENTIC). At <https:\/\/ec.europa.eu\/health\/documents\/community-register\/2017\/20170524137650\/dec_137650_en.pdf>."},{"key":"10.1016\/j.vaccine.2019.09.033_b0085","unstructured":"Koch-Institut, R. Epidemiologisches Bulletin 3\/2018. At <https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2018\/Ausgaben\/03_18.p df?__blob=publicationFile>."},{"key":"10.1016\/j.vaccine.2019.09.033_b0090","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfy225","article-title":"Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab","author":"G\u00e4ckler","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.vaccine.2019.09.033_b0095","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1128\/IAI.01044-09","article-title":"Critical roles of complement and antibodies in host defense mechanisms against Neisseria meningitidis as revealed by human complement genetic deficiencies","volume":"78","author":"Hellerud","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.09.033_b0100","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","article-title":"The effect of rituximab on vaccine responses in patients with immune thrombocytopenia","volume":"122","author":"Nazi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2019.09.033_b0105","unstructured":"The Immunological Basis for Immunization Series; 2010. At <http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/44376\/9789241599849_eng.p df?sequence=1>."},{"key":"10.1016\/j.vaccine.2019.09.033_b0110","unstructured":"ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. At <https:\/\/ec.europa.eu\/health\/documents\/community-register\/2017\/20171030138918\/anx_138918_en.pdf>."},{"key":"10.1016\/j.vaccine.2019.09.033_b0115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.vaccine.2011.10.068","article-title":"Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source","volume":"30","author":"Gill","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.09.033_b0120","unstructured":"Jones S. Mechanisms Responsible for Differential Bactericidal Activities of Human and Rabbit Complement Against Neisseria Meningitidis; 2016. At <https:\/\/orca.cf.ac.uk\/98819\/1\/JonesSPhD2017.pdf>."},{"key":"10.1016\/j.vaccine.2019.09.033_b0125","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/21645515.2017.1264797","article-title":"Recommended vaccinations for asplenic and hyposplenic adult patients","volume":"13","author":"Bonanni","year":"2017","journal-title":"Human Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2019.09.033_b0130","unstructured":"Koch-Institut R. Epidemiologisches Bulletin des Robert Koch-Instituts Ausgabe 34\/2018; 2018. At <www.stiko.de>."},{"key":"10.1016\/j.vaccine.2019.09.033_b0135","unstructured":"Campbell H, Parikh S, Ramsay M, Ladhani S. Guidance for the public health management of meningococcal disease in the UK; 2018. At <https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/688835\/Public_health_management_of_meningococcal_d isease_guidelines.pdf>."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19312423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19312423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:36:28Z","timestamp":1759401388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19312423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":27,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0264410X19312423"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.033","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serologic response to meningococcal vaccination in patients with cold agglutinin disease (CAD) in the novel era of complement inhibition","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}